TY - JOUR

T1 - Xenon in Sub-Anesthetic Doses for Treatment of Major Depression

T2 - 72nd Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry (SOBP)

AU - Aftanas, Lyubomir

AU - Akhmetova, Olga

AU - Brack, Ivan

AU - Danilenko, Konstantin

AU - Khabarov, Alexander

AU - Nikolenko, Ekaterina

PY - 2017/5/15

Y1 - 2017/5/15

N2 - Background: We hypothesized that like ketamine, the general anesthetic and N-methyl-D-aspartate receptor antagonist xenon (Xe) inhaled in sub-anesthetic doses may be an acting treatment for Major Depression Disorder (MDD). Methods: In this randomized, single-blind, placebo-controlled, parallel-group study, 30 patients manifesting moderate or severe MDD were randomly assigned to 10 daily 15 min inhalation session either of 25% Xe/30% oxygen/45% nitrogen (treatment group, n515) or 70% nitrogen/30% oxygen (placebo control, n515). The primary endpoints were the changes on the Beck Depression Inventory (BDI-II) scale. Results: Each 15 min Xe treatment session was performed at a median inspiratory concentration of 17%, while a peak Xe concentration (at a median of 24%) was maintained for 5 min. The treatment was discontinued in 3 patients from the placebo and 1 patient from the Xe groups for emotional discomfort and claustrophobia. No adverse events occurred. The treatment response was indexed by marked decrease of negative affect. According to the 2-way ANOVA with Group (2: Xe, Placebo) as the between factor and TIME (2: before and after treatment) as the repeated measures factor the 10 days inhalation sessions significantly reduced BDI-II scores in both groups (TIME: F(1, 24) 5 47.01, pG-G5 0.001). However, the 2-way GroupTIME interaction (F(1, 24) 5 17.46, pG-G5 0.001) followed by planned comparisons specify significantly more robust antidepressant effect of Xe (at p,.001). Conclusions: Supporting our preliminary observation the findings provide the first placebo-controlled evidence that Xe devoid of ketamine's toxicity sequelae may have marked antidepressant effects in patients with MDD.

AB - Background: We hypothesized that like ketamine, the general anesthetic and N-methyl-D-aspartate receptor antagonist xenon (Xe) inhaled in sub-anesthetic doses may be an acting treatment for Major Depression Disorder (MDD). Methods: In this randomized, single-blind, placebo-controlled, parallel-group study, 30 patients manifesting moderate or severe MDD were randomly assigned to 10 daily 15 min inhalation session either of 25% Xe/30% oxygen/45% nitrogen (treatment group, n515) or 70% nitrogen/30% oxygen (placebo control, n515). The primary endpoints were the changes on the Beck Depression Inventory (BDI-II) scale. Results: Each 15 min Xe treatment session was performed at a median inspiratory concentration of 17%, while a peak Xe concentration (at a median of 24%) was maintained for 5 min. The treatment was discontinued in 3 patients from the placebo and 1 patient from the Xe groups for emotional discomfort and claustrophobia. No adverse events occurred. The treatment response was indexed by marked decrease of negative affect. According to the 2-way ANOVA with Group (2: Xe, Placebo) as the between factor and TIME (2: before and after treatment) as the repeated measures factor the 10 days inhalation sessions significantly reduced BDI-II scores in both groups (TIME: F(1, 24) 5 47.01, pG-G5 0.001). However, the 2-way GroupTIME interaction (F(1, 24) 5 17.46, pG-G5 0.001) followed by planned comparisons specify significantly more robust antidepressant effect of Xe (at p,.001). Conclusions: Supporting our preliminary observation the findings provide the first placebo-controlled evidence that Xe devoid of ketamine's toxicity sequelae may have marked antidepressant effects in patients with MDD.

KW - Major Depressive Disorder (MDD)

KW - Xenon

KW - NMDA antagonists

KW - Novel treatments

UR - https://www.mendeley.com/catalogue/e35749a0-4c76-3c15-8277-678c1f1c910b/

U2 - 10.1016/j.biopsych.2017.02.854

DO - 10.1016/j.biopsych.2017.02.854

M3 - Meeting Abstract

VL - 81

SP - S319-S320

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 10

Y2 - 18 May 2017 through 20 May 2017

ER -